3,829 reports of this reaction
1.4% of all EVOLOCUMAB reports
#14 most reported adverse reaction
INJECTION SITE HAEMORRHAGE is the #14 most commonly reported adverse reaction for EVOLOCUMAB, manufactured by Amgen USA Inc.. There are 3,829 FDA adverse event reports linking EVOLOCUMAB to INJECTION SITE HAEMORRHAGE. This represents approximately 1.4% of all 266,603 adverse event reports for this drug.
Patients taking EVOLOCUMAB who experience injection site haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE HAEMORRHAGE is a less commonly reported adverse event for EVOLOCUMAB, but still significant enough to appear in the safety profile.
In addition to injection site haemorrhage, the following adverse reactions have been reported for EVOLOCUMAB:
The following drugs have also been linked to injection site haemorrhage in FDA adverse event reports:
INJECTION SITE HAEMORRHAGE has been reported as an adverse event in 3,829 FDA reports for EVOLOCUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE HAEMORRHAGE accounts for approximately 1.4% of all adverse event reports for EVOLOCUMAB, making it a notable side effect.
If you experience injection site haemorrhage while taking EVOLOCUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.